Want to see BPTH full AI Analyst Report?

Bio-Path Holdings (BPTH) Earnings Dates, Call Summary & Reports

483 Followers

Earnings Data

Report Date

Aug 18, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

―

Last Year’s EPS

-0.55

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2024

Earnings Call Date:Nov 15, 2024|

% Change Since:

Earnings Call Sentiment|Positive

The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.

Company Guidance

In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.

Expansion of DNAbilize Platform

Initiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.

Progress in Cancer Treatment Trials

Continued advancement of Phase I/Ib clinical trials for BP1001-A in patients with solid tumors and BP1002 in refractory relapsed AML patients.

Publication and Potential of BP1003

Publication in Biomedicines journal highlighting the therapeutic potential of BP1003 in various cancer types, including breast, ovarian, and pancreatic cancer.

Financial Improvements

Net loss decreased to $2.1 million in Q3 2024 from $3.2 million in Q3 2023, with a decrease in research and development expenses.

Rapid Enrollment in Clinical Trials

Faster than projected enrollment for the third dosing cohort of 60 mg/m² in the BP1002 trial, completed within six weeks.

Bio-Path Holdings (BPTH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BPTH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 18, 2026	2026 (Q2)	- / -	-0.553	―	―	―
May 08, 2026	2026 (Q1)	- / -0.03	-0.4	92.75% (+0.37)	―	―
Mar 20, 2026	2025 (Q4)	- / -0.03	2.62	-101.03% (-2.65)	―	―
Nov 14, 2025	2025 (Q3)	-0.40 / -0.11	-0.7	83.71% (+0.59)	―	―
Aug 19, 2025	2025 (Q2)	-0.40 / -0.55	-1.16	52.33% (+0.61)	―	―
May 29, 2025	2025 (Q1)	-0.38 / -0.40	-4.88	91.80% (+4.48)	―	―
Mar 28, 2025	2024 (Q4)	-0.37 / 2.62	-3.43	176.38% (+6.05)	―	―
Nov 15, 2024	2024 (Q3)	-1.02 / -0.70	-6.4	89.06% (+5.70)	―
Aug 15, 2024	2024 (Q2)	-1.54 / -1.16	-10.6	89.06% (+9.44)	―
May 15, 2024	2024 (Q1)	-4.54 / -4.88	-13.2	63.03% (+8.32)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BPTH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2026	$0.06	$0.05	-9.09%
Mar 20, 2026	$0.06	$0.06	0.00%
Nov 14, 2025	$0.09	$0.10	+12.79%
Aug 19, 2025	$0.13	$0.11	-14.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bio-Path Holdings (BPTH) report earnings?

Bio-Path Holdings (BPTH) is schdueled to report earning on Aug 18, 2026, TBA (Confirmed).

What is Bio-Path Holdings (BPTH) earnings time?

Bio-Path Holdings (BPTH) earnings time is at Aug 18, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BPTH EPS forecast?

Currently, no data Available